Table 5.
30-day outcomes
| MIC (N = 422) | CS (N = 422) | p value | Unadjusted OR | Adjusted OR* | |||
|---|---|---|---|---|---|---|---|
| n/N | % | n/N | % | ||||
| Death | 11/422 | 2.6 | 19/422 | 4.5 | 0.137 | 0.568 (0.267–1.208) | 0.893 (0.370–2.156) |
| Cardiovascular death | 5/422 | 1.2 | 16/422 | 3.8 | 0.015 | 0.304 (0.110–0.838) | 0.402 (0.130–1.247) |
| Non-CV death | 6/422 | 1.4 | 3/422 | 0.7 | 0.505 | 2.014 (0.500–8.108) | 4.839 (0.952–24.595) |
| Stroke | 9/422 | 2.1 | 16/422 | 3.8 | 0.155 | 0.553 (0.242–1.266) | 0.524 (0.204–1.342) |
| Acute renal failure | 9/422 | 2.1 | 50/422 | 11.9 | < 0.001 | 0.162 (0.079–0.334) | 0.221 (0.101–0.482) |
| Myocardial infarction | 3/422 | 0.7 | 0 | 0 | 0.249 | n.a | n.a |
| Pacemaker implantation | 14/422 | 3.3 | 47/422 | 11.2 | < 0.001 | 0.273 (0.148–0.504) | 0.307 (0.155–0.608) |
| Repeat MV surgery | 1/422 | 0.2 | 3/422 | 0.7 | 0.624 | 0.332 (0.034–3.202) | 0.825 (0.059–11.464) |
p values and OR that are statistically significant are highlighted in bold
*Adjusted for procedural differences between the two groups: MV repair, MV replacement, Cryoablation, LAA closure, concomitant TVR; CV cardiovascular, MV mitral valve